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We presented an extremely severe case of tuberous scle-
rosis complex (TSC) in a female patient with recurring, life-
threatening bleeding complications related to renal angi-
omyolipomas. Massive intratumoral hemorrhage required 
surgical removal of both angiomyolipomatous kidneys 
and kidney transplantation. During the follow-up period, 
the patient developed severe metrorrhagia that eventually 
led to hysterectomy and salpingo-oophorectomy. Bleed-
ing from the operative sites caused the loss of the first kid-
ney transplant received from the mother, and immediate 
hemorrhagic shock led to the loss of the second, cadaveric 
kidney allograft. The third kidney transplant had a success-
ful outcome. Pathological analysis of all tissue specimens 
showed TSC-associated lesions and deformed blood ves-
sels in the surgically removed organs. Molecular genetic 
analysis of TSC1 and TSC2 in the DNA of peripheral leuko-
cytes identified a novel TSC2 c.3599G>C (p.R1200P) variant. 
Functional assessment confirmed the likely pathogenicity 
of the TSC2 c.3599G>C (p.R1200P) variant. To the best of 
our knowledge, this is the first report of the c.3599G>C 
(p.R1200P) variant in exon 29 of the TSC2 gene related to a 
severe clinical course and multiple kidney transplants in a 
patient with TSC.
Received: April 29, 2017
Accepted: December 20, 2017
Correspondence to: 
Zlatko Trobonjača 
Department of Physiology and 
Immunology 
University of Rijeka School of 
Medicine 
Braće Branchetta 20 
51000 Rijeka, Croatia 
zlatko.trobonjaca@uniri.hr
Stela Živčić-Ćosić1, Karin 
Mayer2, Gordana Đorđević3, 
Mark Nellist4, Marianne 
Hoogeveen-Westerveld4, 
Damir Miletić5, Sanjin 
Rački1, Hanns-Georg Klein2, 
Zlatko Trobonjača6
1Department of Nephrology, 
Dialysis and Kidney Transplantation, 
Department of Internal Medicine, 
University Hospital Center Rijeka 
and Faculty of Medicine, University 
of Rijeka, Croatia
2Center for Human Genetics 
and Laboratory Diagnostics, 
Department of Molecular Genetics, 
Dr. Klein, Dr. Rost and colleagues, 
Martinsried, Germany
3Department of Pathology, Faculty 
of Medicine, University of Rijeka, 
Rijeka, Croatia
4Department of Clinical Genetics, 
Erasmus Medical Center, 
Rotterdam, the Netherlands
5Department of Radiology, 
University Hospital Center Rijeka 
and Faculty of Medicine, University 
of Rijeka, Rijeka, Croatia
6Department of Physiology and 
Immunology, Faculty of Medicine, 
University of Rijeka, Rijeka, Croatia
Severe bleeding complications 
and multiple kidney transplants 
in a patient with tuberous 
sclerosis complex caused by a 
novel TSC2 missense variant
CASE REPORT 
 
Croat Med J. 2017;58:416-23 
https://doi.org/10.3325/cmj.2017.58.416
417Živčić-Ćosić et al: Tuberous sclerosis complex caused by a novel TSC2 missense variant
www.cmj.hr
Tuberous sclerosis complex (TSC) is an inherited system-
ic disease caused by mutations in either the TSC1 or TSC2 
gene (1). The TSC1 and TSC2 protein products, hamartin 
(TSC1) and tuberin (TSC2), form the TSC complex that inte-
grates multiple signals to regulate the activity of the mecha-
nistic target of rapamycin (mTOR) complex 1 (TORC1) and, 
thereby, control cell growth. Inactivation of the TSC com-
plex, which results from the combination of a germline and 
somatic mutation, leads to the formation of hamartomas in 
multiple organs, causing highly variable clinical manifesta-
tions of the disease (2-4). TSC-associated loss of renal func-
tion is most often caused by large angiomyolipomas, which 
contain deformed blood vessels with a tendency to form an-
eurysms and bleed (5-7). Nephrectomy is usually required to 
stop the bleeding, followed by eventual kidney transplanta-
tion (2,3). Although end-stage renal failure is rare, kidney dis-
ease has become the leading cause of death in TSC patients 
(8,9). Furthermore, mortality rates in TSC patients, especially 
those with low cognitive function, are generally increased in 
comparison with that of general population (7).
We present a case of a female patient with severe TSC 
complicated by recurring, life-threatening postoperative 
bleeding episodes, whose tissue specimens from surgical-
ly removed organs were analyzed using standard patho-
logical and immunohistological methods. The performed 
molecular genetic analysis of TSC1 and TSC2 identified a 
novel TSC2 variant in the patient’s leukocyte DNA and the 
pathogenicity of the variant was confirmed by functional 
assessment (10).
CaSe RepoRT
Our female patient received the diagnosis of TSC in child-
hood on the basis of epilepsy, learning disability, and fa-
cial angiofibromas (Table 1). In 2003, at the age of 18, the 
Table 1. Timeline of the patient’s clinical course
blood transfusions (units)









Epileptic seizures localized to the left arm - - -
Childhood Epilepsy, learning disability and facial angiofibromas - - -
















Reccurent retroperitoneal hemorrhage followed by left nephrectomy with 
simultanous living kidney transplantation
Uroinfections, bronchopneumonia




Severe metrorrhagia with worsening of allograft function followed by 
hysterectomy and left salpingo-oophorectomy
Postoperative hemorrhage causing hydronephrosis, loss of allograft function 
and hemorrhagic shock followed by urgent transplantectomy
Massive postoperative hemorrhage and sepsis
Start of dialysis treatment
62 (17 filtered) 21 48
26 years
(2011)
Second kidney transplantation and severe postoperative bleeding followed by 
transplantectomy
Sepsis (Haemophilus influenzae)
38 filtered 12 -
25-28 years
(2010-2013)
Frequent readmissions due to central venous catheter-related complications 2 filtered - -
28 years
(2013)
Third kidney transplantation with severe intra- and postoperative 
hemodynamic instability requiring high doses of norepinephrine
Bacteremia and accelerated acute cellular rejection
Patient recovery and excellent graft function
5 filtered - -
Total 107 (54 
filtered)
33 48
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patient underwent right nephrectomy due to a giant an-
giomyolipoma that caused severe retroperitoneal hemor-
rhage. In 2006, contralateral nephrectomy with simultane-
ous kidney transplantation was performed due to a giant 
angiomyolipoma of the left kidney and hemorrhage. The 
patient received the kidney transplant from the mother.
In 2010, the patient underwent hysterectomy with unilat-
eral salpingo-oophorectomy due to prolonged metror-
rhagia unresponsive to medical treatment and massive 
ovarian edema. Bleeding from the operation site caused 
hemorrhagic shock and kidney allograft loss. After recov-
ery, then 26-year-old patient underwent urgent cadaveric 
kidney transplantation due to the imminent loss of dialysis 
access and non-compliance with dialysis treatment. Again, 
a severe bleeding episode from the operative site occurred 
resulting in arterial thrombosis of the allograft and trans-
plantectomy. During the following 1.5 years, the patient 
was frequently readmitted due to the central venous cath-
eter-related complications, such as bacteremia, clotting, 
and self-removal of the catheter due to non-compliance. 
Because of mental retardation, fear, and non-compliance, 
all catheter manipulations and diagnostic or treatment 
procedures had to be performed under general anesthe-
sia. It was not possible to create and use an arteriovenous 
fistula as dialysis access. At the age of 28, the patient was 
approved for another cadaveric kidney transplant. Follow-
ing numerous blood transfusions (102 units of erythrocyte 
concentrates, 33 units of fresh frozen plasma, and 48 units 
of platelet concentrates) and two kidney transplantations, 
the patient became sensitized, with 3% current (7% high-
est) panel reactive antibodies. During the transplant pro-
cedure, the patient required hemodynamic stabilization by 
volume substitution, transfusion of filtered erythrocytes, 
and administration of high doses of norepinephrine. The 
postoperative course was complicated by methicillin-re-
FiGuRe 1. The angiomyolipomatous kidney and veins in the normal renal hilum with incompletely developed smooth muscle 
layers in the patient with severe form of tuberous sclerosis complex (TSC). A. The giant angiomyolipomatous right kidney (2.65 kg; 
25 × 16 × 14 cm) compressed the renal pelvis and spread into the surrounding fatty tissue. B. The angiomyolipoma was composed of 
mature adipocytes, small and medium-sized blood vessels surrounded by collaretes of smooth muscle cells, with focally epithelioid 
appearance (hematoxylin-eosin, 100X). C. Spindle-shaped smooth muscle cells were positive for the neuroectodermal marker Hu-
man Melanoma black (HMb)-45 (200X). D. The smooth muscle layer of veins in the normal renal hilum was incompletely developed 
and showed a focally positive expression of HMb-45 (100X).
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sistant Staphylococcus aureus bacteremia and accelerated 
acute cellular rejection. The patient responded well to the 
parenteral antibiotic and antirejection treatment and al-
lograft function eventually stabilized.
Besides a higher fibrinogen level, preoperative coagulation 
parameters were always within the normal range. Radio-
logic imaging, performed due to the hemorrhagic shock 
and sepsis after the loss of the first kidney allograft, con-
firmed numerous TSC-associated lesions in the liver, lungs, 
and brain. Our patient was the only family member with 
clinical signs of TSC. Genetic analysis of other family mem-
bers was not performed, because they had no signs of TSC 
and did not want to know their genetic background.
pathological findings
All tissue specimens were fixed and stained according 
to standard protocols with hematoxylin-eosin, and Van 
Gieson elastica, and immunohistochemically with prima-
ry antibodies including alpha-smooth muscle actin (SMA), 
Desmin, Human Melanoma Black (HMB)-45, Melan-A, Pan-
Cytokeratin, D240, estrogen receptor α, progesterone re-
ceptor, and cluster of differentiation (CD) 68.
Kidney specimens. Macroscopically, both kidneys were 
enormously enlarged, and the normal tissue was almost 
completely replaced by tumor tissue with areas of necrosis 
and hemorrhage, which compressed the renal pelvis and 
spread into the surrounding fatty tissue (Figure 1A). Histo-
logical and immunohistochemical findings corresponded 
to angiomyolipoma. Spindle cells were positive for SMA, 
HMB-45, and Melan-A (Figures 1B-D). The smooth muscle 
layer of veins in the normal renal hilum was incompletely 
developed (Figure 1D).
Hysterectomy and salpingo-oophorectomy specimens. The 
uterus had a thickened endometrium showing simple hy-
perplasia. The myometrium had foci of lymphangioleio-
myomatosis (LAM), positive for HMB-45 and D240 staining 
(Figure 2A; data not shown). Both ovaries were enlarged 
and contained multiple cysts, most likely involuting follicu-
lar cysts. The dominant finding in the left ovary was a mas-
sive edema and foci showing abnormal lymphatic vessel 
proliferation (Figure 2B).
Molecular genetic analysis
All 21 coding exons of the TSC1 gene and all 41 coding 
exons of the TSC2 gene, including the adjacent intronic 
sequences, were amplified using polymerase chain reac-
tion (PCR) on genomic DNA extracted from peripheral leu-
kocytes. The amplicons were directly sequenced by cap-
illary electrophoresis using the Big Dye technology (Life 
Technologies, Darmstadt, Germany). For comparison and 
assessment of variants, the National Center for Biotech-
nology Information (NCBI) database (dbSNP, Bethesda 
MD, USA), the Exome Variant Server (NHLBI GO Exome Se-
quencing Project (ESP), Seattle, WA, USA), the Exome Ag-
gregation Consortium (ExAC, Cambridge, MA, USA), the 
Human Gene Mutation Database (HGMD® professional 
release, Cardiff, UK), and the TSC locus-specific sequence 
variation database (LOVD, Leiden, The Netherlands) were 
used. cDNA reference sequences were NM_000368.4 for 
TSC1 and NM_000548.3 for TSC2. According to historical 
convention, the exons of TSC2 were numbered from the 
FiGuRe 2. Tuberous sclerosis complex (TSC)-associated lesions 
found in the myometrium and ovaries of the patient. immuno-
histochemistry revealed suspicious foci of uterine lymphangio-
leiomyomatosis, with Human Melanoma black (HMb)-45 
positivity in cells of vascular vessel walls. A. The arrow shows 
HMb-45 positive cells (400X). B. The left ovary was massively 
edematous and contained foci of abnormal lymphatic vessel 
proliferation (hematoxylin-eosin, 40X).
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first coding exon. For the in silico prediction of variants with 
unknown clinical significance, algorithms of PolyPhen-2, 
Sorts Intolerant From Tolerant (SIFT), Align-Grantham Vari-
ation Grantham Deviation (Align-GVGD), MutationTaster, 
Single Nucleotide Polymorphism Database & Gene On-
tology (SNPs&GO), MutPred, MutationAssessor, and Func-
tional Analysis Through Hidden Markov Models (FATHMM) 
were applied. For the detection of genomic deletions and 
duplications, a quantitative analysis of all 23 TSC1 exons 
and all 42 TSC2 exons was carried out using Multiplex Liga-
tion Probe Amplification (MLPA; SALSA-Kit P124-C1, 0112, 
and P046-C1, 1011, MRC-Holland, Amsterdam, The Neth-
erlands).
A heterozygous TSC2 c.3599G>C (p.R1200P) (exon 29) vari-
ant was detected in patient’s leukocyte DNA. No other vari-
ant or genomic deletion or duplication was identified in ei-
ther TSC1 or TSC2. DNA samples from the parents or other 
family members were not available for testing.
Functional assessment of the TSC2 c.3599G>C 
(p.R1200p) variant
An expression construct for the TSC2 c.3599G>C (p.R1200P) 
variant was derived by site-directed mutagenesis (SDM) of 
the wild-type TSC2 expression construct (1). The construct 
was verified by sequencing the complete open read-
ing frame; no additional nucleotide changes were intro-
duced during the SDM procedure. Functional assessment 
was performed as described previously (1). The tuberin 
p.R1200P variant (R1200P) was compared with wild-type 
tuberin, the pathogenic p.R611Q (R611Q) variant, cells not 
expressing tuberin (TSC1/S6K) and cells transfected with 
the pcDNA3 expression vector only (mock). A p70 S6 ki-
nase (S6K) reporter construct and TSC1 expression con-
struct were included in each transfection mixture, except 
for the mock. The total S6K signal measured by immuno-
blotting was used to estimate the relative transfection ef-
ficiency for each variant construct. The ratio of the signals 
for T389-phosphorylated S6K and total S6K (T389/S6K ra-
FiGuRe 3. Functional assessment of the tuberous sclerosis complex (TSC) TSC2 c.3599G>C (p.R1200p) variant showed a significantly 
increased T389-phosphorylated p70 S6 kinase/ total p70 S6 kinase (T389/S6K) ratio. The signals for TSC2, TSC1, total S6K (S6K), and 
T389-phosphorylated S6K (T389) were determined per variant, relative to the wild-type control (TSC2) in four independent transfec-
tion experiments. The mean TSC2 (A), TSC1 (B), and S6K (D) signals, and mean T389/S6K ratio (C) are shown for each variant. in each 
case the dotted line indicates the signal or ratio for wild-type TSC2 ( = 1.0). error bars represent the standard error of the mean; 
variants that were significantly different from the wild-type control (TSC2) are indicated with an asterisk (P < 0.050; Student’s t test). 
amino acid changes are given according to TSC2 cDNa reference transcript sequence NM_000548.3.
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tio) was used to estimate TORC1 activity. The TSC2, TSC1, 
S6K, and T389-phosphorylated S6K signals were estimated 
by immunoblotting in four independent transfection ex-
periments.
Functional assessment of the TSC2 c.3599G>C (p.R1200P) 
variant indicated that the variant disrupted TSC complex 
function and was, therefore, likely to be pathogenic. The 
T389/S6K ratio was significantly increased, indicating im-
paired inhibition of TORC1 (Figure 3).
DiSCuSSioN
We described the case of a female patient with serious 
TSC-associated complications, including mental retarda-
tion, recurrent hemorrhage, and the need for renal re-
placement therapy due to angiomyolipomas. At the time 
when angiomyolipomas were detected in our patient, the 
beneficial effects of mTOR inhibitors had not yet been es-
tablished and kidney preserving procedures, such as arte-
rial embolization or partial nephrectomy, were not feasible 
(2,3,7). Although angiomyolipomas are usually benign tu-
mors, sometimes they can be aggressive, such as epithe-
lioid angiomyolipomas (11). In our patient, pathohistologi-
cal analysis revealed foci of epithelioid cells throughout the 
tumors. Giant angiomyolipomas completely replaced both 
kidneys and induced recurrent retroperitoneal bleeding.
Hemorrhage is known to be a major complication of these 
vascular tumors (3,5,7). Uterine lesions associated with TSC, 
such as lymphangioleiomyomatosis, angiomyoma or an-
giomyolipoma, may lead to bleeding disturbances (12). 
In our patient, metrorrhagia required hysterectomy, and 
postoperative hemorrhage caused the loss of two kid-
ney allografts. We did not find any report on such bleed-
ing complications after bilateral nephrectomy, even dur-
ing long-term follow-up of TSC patients with a functional 
transplant. As there was no identifiable cause, we suspect-
ed that these postoperative bleeding episodes could be 
related to a multifocal anomaly in the development of the 
blood vessel wall.
The discovery of the molecular function of TSC1 and TSC2 
and their involvement in TORC1 signaling provided tre-
mendous insight into the pathogenesis of the disease. Hy-
peractive TORC1 signaling was shown to lead to abnormal 
vasculogenesis in TSC (4,13). The formation of arterial an-
eurysms in many organs is probably facilitated by abnor-
mal elastin-poor structures in blood vessel walls in TSC-
associated lesions (14). In our patient, the finding of focal 
expression of HMB-45 in vessel walls in the vicinity of the 
renal tumor indicated a multifocal growth pattern of angio-
myolipoma. We noticed the characteristic co-expression of 
melanocytic (HMB-45, Melan A), histiocytic (CD68), and 
smooth muscle (SMA) markers (data not shown), which 
supports the unique nature of angiomyolipoma as a tu-
mor with the ability for different phenotypic and immuno-
typic presentations (14). The abnormal ovarian lymphatic 
vessel proliferation, massive ovarian edema, multiple cystic 
formations in both ovaries, and uterine foci of proliferating 
LAM cells (abnormal smooth muscle-like cells) in our pa-
tient indicated the presence of generalized TSC-associated 
lesions. They could be the result of multicentric LAM cell 
proliferation, leading to the formation of fluid-filled cystic 
structures and hamartomas. LAM cells have heterogeneous 
HMB-45 reactivity, which has been related to the level of 
tuberin expression. It has been shown that an epigenetic 
alteration of TSC2 can cause the loss of tuberin in TSC cells 
(15). TSC2-deficient smooth-muscle cells have a higher po-
tential for migration than normal cells in vitro (15). A better 
understanding of the role of hamartin and tuberin in cell 
mobility and adhesion will further improve insight on the 
development of tumor deposits (4,14). Pharmacological 
therapy should target both the proliferation and migration 
of LAM cells in TSC. mTOR inhibitors, which have the ability 
to decrease the number of LAM cells in blood and urine, 
are recognized as therapeutic agents for the prevention of 
angiomyolipoma growth and kidney function loss (3,16).
According to the current diagnostic criteria, a diagnosis 
of TSC can be established clinically or genetically through 
the identification of a pathogenic TSC1 or TSC2 mutation 
(2). In families with several affected members, mutations 
are equally distributed between TSC1 and TSC2. In our pa-
tient, molecular genetic examination of DNA in peripheral 
leukocytes identified the heterozygous variant c.3599G>C, 
(p.R1200P) in exon 29 of the TSC2 gene. MLPA analysis did 
not reveal any genomic deletions or duplications in either 
TSC1 or TSC2. The majority of TSC cases are sporadic (17). 
Sporadic cases mostly have a TSC2 mutation, with TSC2 
mutations being associated with more severe forms of TSC 
disease (18). Our patient was the only family member with 
clinical signs of TSC. However, we can only speculate that 
her case was sporadic because other family members re-
fused the testing.
The TSC2 c.3599G>C (p.R1200P) variant has been included 
in the tuberous sclerosis database (LOVD), but without any 
information on the patients’ clinical manifestations. The 
variant is not included in the ESP or ExAC databases. 
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The variant leads to the exchange of a highly conserved ba-
sic amino acid with a hydrophobic amino acid with moder-
ate physicochemical differences. All the algorithms tested 
predicted a likely pathogenic impact on protein structure 
and function. Functional assessment demonstrated a sig-
nificantly increased ratio of T389-phosphorylated S6K: total 
S6K (T389/S6K ratio) compared to wild-type TSC2, but not 
significantly different from the T389/S6K ratio of a known 
pathogenic variant, TSC2 c.1832G>A (p.R611Q), indicating 
impaired inhibition of TORC1. Another variant in the same 
codon, c.3598C>T (p.R1200W), has been identified in sev-
eral TSC patients, some of whom had a mild phenotype 
and reduced risk of infantile spasms (19). The observation 
that the p.R1200W variant also affects the tuberin-depen-
dent inhibition of TORC1 (1) highlights the importance of 
amino acid position 1200 for tuberin function. Our study 
was limited by the fact that TSC with end-stage renal dis-
ease is a rare condition and we did not find any similar 
cases in the literature. Also, the genetic background was 
not further investigated because other family members re-
fused genetic analysis.
This case report highlights the association of the patho-
genic missense variant (p.R1200P) in the TSC2 gene with 
a severe clinical course of TSC. The development of giant 
angiomyolipomas and generalized TSC-associated lesions 
caused organ loss and life-threatening hemorrhage. After 
many years of difficult treatment, our patient was submit-
ted to third kidney transplantation with a successful out-
come. Further research is needed to determine the extent 
of TSC-associated lesions and clinical manifestations relat-
ed to this pathogenic missense variant.
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